Evaluation of the repeated-dose liver and gastrointestinal tract micronucleus assays with 22 chemicals using young adult rats: summary of the collaborative study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/The Japanese Environmental Mutagen Society (JEMS) - Mammalian Mutagenicity Study Group (MMS)
Shuichi Hamada,Wakako Ohyama,Rie Takashima,Keisuke Shimada,Kazumi Matsumoto,Satoru Kawakami,Fuyumi Uno,Hajime Sui,Yasushi Shimada,Tadashi Imamura,Shoji Matsumura,Hisakazu Sanada,Kenji Inoue,Shigeharu Muto,Izumi Ogawa,Aya Hayashi,Tomomi Takayanagi,Yosuke Ogiwara,Akihisa Maeda,Emiko Okada,Yukari Terashima,Hironao Takasawa,Kazunori Narumi,Yumi Wako,Kazufumi Kawasako,Masaki Sano,Nobuyuki Ohashi,Takeshi Morita,Hajime Kojima,Masamitsu Honma,Makoto Hayashi
DOI: https://doi.org/10.1016/j.mrgentox.2015.01.001
Abstract:The repeated-dose liver micronucleus (RDLMN) assay using young adult rats has the potential to detect hepatocarcinogens. We conducted a collaborative study to assess the performance of this assay and to evaluate the possibility of integrating it into general toxicological studies. Twenty-four testing laboratories belonging to the Mammalian Mutagenicity Study Group, a subgroup of the Japanese Environmental Mutagen Society, participated in this trial. Twenty-two model chemicals, including some hepatocarcinogens, were tested in 14- and/or 28-day RDLMN assays. As a result, 14 out of the 16 hepatocarcinogens were positive, including 9 genotoxic hepatocarcinogens, which were reported negative in the bone marrow/peripheral blood micronucleus (MN) assay by a single treatment. These outcomes show the high sensitivity of the RDLMN assay to hepatocarcinogens. Regarding the specificity, 4 out of the 6 non-liver targeted genotoxic carcinogens gave negative responses. This shows the high organ specificity of the RDLMN assay. In addition to the RDLMN assay, we simultaneously conducted gastrointestinal tract MN assays using 6 of the above carcinogens as an optional trial of the collaborative study. The MN assay using the glandular stomach, which is the first contact site of the test chemical when administered by oral gavage, was able to detect chromosomal aberrations with 3 test chemicals including a stomach-targeted carcinogen. The treatment regime was the 14- and/or 28-day repeated-dose, and the regime is sufficiently promising to incorporate these methods into repeated-dose toxicological studies. The outcomes of our collaborative study indicated that the new techniques to detect chromosomal aberrations in vivo in several tissues worked successfully.